Key Points
- Director Amy McBride Wendell sold 43,684 shares on December 16 at an average price of $29.31 for about $1.28M, trimming her holding by 31.77% to 93,826 shares (≈$2.75M).
- Analyst sentiment is mostly bullish — nine Buy ratings vs one Sell and a consensus target of $35.56, with recent price-target raises up to $37.
- Strong quarter but lingering fundamentals concerns: AxoGen reported $0.12 EPS (vs $0.09 est.) and $60.08M revenue, yet retains a negative net margin (-0.98%) and consensus expects -0.29 EPS for the year; market cap is ~$1.45B with a negative P/E.
AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) CFO Lindsey Marie Hartley sold 14,812 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $29.86, for a total value of $442,286.32. Following the transaction, the chief financial officer owned 31,376 shares of the company's stock, valued at $936,887.36. The trade was a 32.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Lindsey Marie Hartley also recently made the following trade(s):
- On Monday, December 8th, Lindsey Marie Hartley sold 14,387 shares of AxoGen stock. The stock was sold at an average price of $31.56, for a total transaction of $454,053.72.
AxoGen Stock Performance
Shares of NASDAQ AXGN traded up $0.83 during mid-day trading on Thursday, hitting $32.22. The company had a trading volume of 58,892 shares, compared to its average volume of 852,076. The company has a current ratio of 4.09, a quick ratio of 2.64 and a debt-to-equity ratio of 0.54. AxoGen, Inc. has a 1 year low of $9.22 and a 1 year high of $34.24. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -641.82 and a beta of 1.06. The stock's 50-day moving average price is $24.09 and its 200-day moving average price is $17.35.
AxoGen (NASDAQ:AXGN - Get Free Report) last issued its earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 EPS for the quarter, topping the consensus estimate of $0.09 by $0.03. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%.The business had revenue of $60.08 million during the quarter, compared to the consensus estimate of $56.90 million. On average, sell-side analysts forecast that AxoGen, Inc. will post -0.29 earnings per share for the current year.
Institutional Trading of AxoGen
Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of AxoGen by 4.6% in the first quarter. Vanguard Group Inc. now owns 2,538,607 shares of the medical equipment provider's stock worth $46,964,000 after buying an additional 112,679 shares during the period. Swiss National Bank bought a new position in AxoGen during the 1st quarter worth approximately $1,498,000. Invesco Ltd. increased its stake in AxoGen by 2,124.5% in the 1st quarter. Invesco Ltd. now owns 382,429 shares of the medical equipment provider's stock worth $7,075,000 after purchasing an additional 365,237 shares during the period. Nuveen LLC bought a new stake in AxoGen during the 1st quarter valued at $5,668,000. Finally, Algert Global LLC grew its holdings in AxoGen by 101.1% in the 1st quarter. Algert Global LLC now owns 28,520 shares of the medical equipment provider's stock worth $528,000 after acquiring an additional 14,340 shares during the last quarter. 80.29% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on AXGN shares. Canaccord Genuity Group boosted their price target on shares of AxoGen from $27.00 to $37.00 and gave the company a "buy" rating in a research report on Friday, December 5th. JMP Securities set a $34.00 target price on AxoGen in a research report on Thursday, October 30th. Mizuho started coverage on AxoGen in a research report on Monday, December 1st. They set an "outperform" rating and a $40.00 price target for the company. Citigroup restated a "market outperform" rating on shares of AxoGen in a research report on Thursday, October 30th. Finally, Lake Street Capital lifted their price objective on shares of AxoGen from $30.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, December 4th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AxoGen currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.56.
Read Our Latest Stock Analysis on AxoGen
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
